Current State of Therapeutics for HTLV-1
Open accessThe DOI matches its Crossref record; 353 of the 372 references it cites were found in a registry or an index; 84 of the 236 sources its claims cite were checked for support.
Abstract
Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5–10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4+ T cells and remains in a state of reduced transcription, often being asymptomatic in the beginning of infection, with symptoms developing later in life. HTLV-1 infection is implicated in the development of adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM), amongst other immune-related disorders. With no preventive or curative interventions, infected individuals have limited treatment options, most of which manage symptoms. The clinical burden and lack of treatment options directs the need for alternative treatment strategies for HTLV-1 infection. Recent advances have been made in the development of RNA-based antiviral therapeutics for Human Immunodeficiency Virus Type-1 (HIV-1), an analogous retrovirus that shares modes of transmission with HTLV-1. This review highlights past and ongoing efforts in the development of HTLV-1 therapeutics and vaccines, with a focus on the potential for gene therapy as a new treatment modality in light of its successes in HIV-1, as well as animal models that may help the advancement of novel antiviral and anticancer interventions.
Overview
CoChat Summary
## TL;DR
This review argues that HTLV-1 still lacks approved curative or preventive therapy, and that current treatment is largely symptomatic or repurposed from HIV and oncology drugs. It highlights gene-targeting approaches, especially RNAi and gene editing, plus BLV vaccination as the most promising directions for future HTLV-1 interventions.
## Key findings
- HTLV-1 causes lifelong infection in an estimated ~5–10 million people globally, with global prevalence estimates ranging from 3 to 30 million cases.
- The lifetime risk of ATL in carriers is estimated at 1–5%, and the risk of HAM at about 3%; among carriers, the risk of early neurological disorders can be as high as 24%.
- Existing ART has limited impact because it cannot eliminate HTLV-1 reservoirs driven by clonal expansion; for example, AZT + lamivudine in a randomized double-blind placebo-controlled HAM trial produced no significant reduction in PVL or clinical measures after 24 weeks.
- In HAM, a multicentre randomized phase III mogamulizumab study found no significant difference in the primary or secondary motor endpoints at the end of the double-blind period, but it did significantly reduce PVL and CSF CXCL10/neopterin; earlier phase I/IIa data in 21 patients reported improved motor ability in 32% and reduced spasticity in 79%.
- The BLV vaccine is presented as a model for HTLV-1 vaccination: in Argentina it conferred immunity in 28 of 29 cows over 4 years and was reported as safe and effective.
## Methods
- Narrative review of past and ongoing HTLV-1 therapeutics and vaccines, with emphasis on similarities to HIV-1 and on gene therapy/RNA-based approaches.
- Synthesizes evidence from cell models, animal models (mice, rabbits, non-human primates, humanized mice), and clinical studies/trials in ATL and HAM.
- Main analysis is comparative and descriptive, evaluating how different therapeutic strategies affect PVL, viral gene expression, tumor burden, and clinical outcomes.
## Limitations
- The paper states that there are no preventive or curative interventions for HTLV-1 and that there are no approved HTLV-1-specific inhibitors or antiviral ASOs.
- For HAM and other HTLV-1-associated inflammatory diseases, the paper notes that studies are often observational, with small cohorts and geographic constraints.
- Evident from the text: much of the evidence comes from preclinical models, and the review itself notes major gaps in in vivo/in vitro HTLV-1 studies, efficient delivery for gene therapies, and clinical translation of RNAi/gene-editing approaches.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
63 Valid · 10 Not valid · 85 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HTLV-1 is primarily associated with the aggressive haematological malignancy ATL [1,2] and a chronic inflammatory disease called HTLV-1-associated myelopathies (HAM).”
§ Current State of Therapeutics for HTLV-1 > 1. Introduction > 1.5. HTLV-1-Associated Diseases
What the sources say
- Partly supportedcites [1] Poiesz, 1980, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The paper reports HTLV particles in lymphocytes from a patient with cutaneous T-cell lymphoma (mycosis fungoides), supporting an association with a T-cell malignancy. It does not establish the more specific claim that HTLV-1 is primarily associated with ATL. The citation in the printed sentence is attached to ATL, not HAM. (LLM, conf=0.78)
- Partly supportedcites [2] Hinuma, 1981, Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
Our copy of Hinuma et al. 1981 supports only the ATL half of the sentence: the Abstract and Results (p. 1-2) report anti-ATLA antibodies in all 44 ATL patients and in most T-cell lymphoma patients, and the Introduction describes ATL as a rapidly progressing, treatment-resistant malignancy — though the paper hedges the link ('The present results suggest, but do not prove a causal relationship between a type C virus and ATL', DISCUSSION) and never uses the name HTLV-1, calling the antigen ATLA and the particle a type C virus. The second attributed element, association with HTLV-1-associated myelopathy (HAM), is absent: searches for 'myelopathy', 'HAM' and 'tropical spastic paraparesis' returned no passage in our copy. The HAM association is therefore not supported by this source. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An ongoing issue of HTLV-1-infected cell lines is the underrepresentation of more divergent subtypes, with recent studies suggesting that different HTLV-1 subtypes exert significantly different influences over the host immune system compared to the dominant cosmopolitan subtype [19].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Partly supportedcites [19] Afonso, 2019, Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes, Retrovirology sourceExperimental — accuracy not yet measured
In “The genetic organization differs according to molecular genotypes” (page not provided), the review says HTLV-1b and HTLV-1c lack some accessory genes present in HTLV-1a and that one HTLV-1a accessory protein facilitates immune escape. It does not establish that different subtypes exert significantly different effects on the host immune system; it presents the implications of those genetic differences as hypotheses. (LLM, conf=0.83)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“with previous studies suggesting a distinct pathogenesis [96,118,119,120].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Not checked — no full text of the sourcecites [96] Einsiedel, 2012, Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population, Clin. Infect. Dis. source
- Could not verifycites [118] Talukder, M.R., Pham, H., Woodman, R., Wilson, K., Taylor, K., Kaldor, J., and Einsiedel, L. (2022). The Association between Diabetes and Human T-Cell Leukaemia Virus Type-1 (HTLV-1) with Strongyloides stercoralis: Results of a Community-Based, Cross-Sectional Survey in Central Australia. Int. J. Environ. Res. Public Health, 19. sourceExperimental — accuracy not yet measured
The Introduction describes immune effects of HTLV-1 infection in people with Strongyloides, and Methods §2.5 mentions HTLV-1c only to identify the sequence targeted by a test. Neither passage says HTLV-1c has a distinct pathogenesis. Searches for “pathogenesis” and subtype-specific differences found no passage addressing that claim. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [119] Talukder, 2021, Risk factors for HTLV-1, acute kidney injury, and urinary tract infection among aboriginal adults with end stage kidney disease in central Australia, J. Med. Virol. source
- Not checked — no full text of the sourcecites [120] Talukder, 2023, High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia, Clin. Infect. Dis. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overexpression of Hbz was observed to prevent Tax-induced NF-κB and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.2. Animal Models
What the sources say
- Supportedcites [157] Akkouche, A., Moodad, S., Hleihel, R., Skayneh, H., Chambeyron, S., El Hajj, H., and Bazarbachi, A. (2021). In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ. PLoS Pathog., 17. source
The Results section reports that flies overexpressing both HBZ and Tax had significantly attenuated Tax-mediated NF-κB and PRC2 activation compared with flies expressing Tax alone; its Fig. 3 caption describes this as abrogation. A separate Results section reports that HBZ overexpression blocked Tax-induced PRC2 activation in human cells. Page numbers were not available in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The cessation of therapy in HIV is associated with a strong viral rebound to pre-therapeutic plasma viral loads [164,165,166]”
§ Current State of Therapeutics for HTLV-1 > 3. Current Treatments > 3.1. Antiretroviral Therapies and Limitations for HTLV-1
What the sources say
- Supportedcites [164] Hamlyn, E., Ewings, F.M., Porter, K., Cooper, D.A., Tambussi, G., Schechter, M., Pedersen, C., Okulicz, J.F., McClure, M., and Babiker, A. (2012). Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE, 7. source
The Introduction states that plasma viral load after ART cessation can reach levels comparable to pre-treatment values. The Discussion also reports that participants who began ART during primary HIV infection reached pre-ART viral-load levels after a median of 50 weeks. (LLM, conf=0.92)
- Partly supportedcites [165] Chun, 2010, Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication, AIDS sourceExperimental — accuracy not yet measured
The Results report that plasma viremia rebounded after ART was stopped in one participant, reaching 1,593 and later 8,684 HIV RNA copies/ml. The Discussion says rebound is likely for the vast majority of people receiving ART. Neither passage establishes that viral loads returned to pre-therapy levels; the reported rebound was also delayed by 50 days in the participant studied. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [166] Colven, 2000, Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection, Ann. Intern. Med. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
60 more claims · 17 with their cited sources checked
Create a free account to see all 209 claims and to verify the 40 references still open.
- It may state two separate claims as one. 103
- Probably not a substantial claim. 64
- The quote only partly states this claim. 2
Citations
Cites
Items 201–353 of 353
Demontis, M. A., Sadiq, M. T., Golz, S., & Taylor, G. P. (2015) · Journal of Medical Virology · doi:10.1002/jmv.24264 · Cited by 59 · cited 1×
“As the virus predominately affects host immune cells causing subclinical immune suppression, HTLV-1 infection is also linked with an elevated rate of opportunistic infections.”
BackgroundFukumoto, R., Andresen, V., Bialuk, I., Cecchinato, V., Walser, J.-C., Valeri, V. W., Nauroth, J. M., Gessain, A., Nicot, C., & Franchini, G. (2009) · Blood · doi:10.1182/blood-2008-04-146928 · Cited by 59
Gessain, A. (2011) · Bulletin de la Société de pathologie exotique · doi:10.1007/s13149-011-0174-4 · Cited by 58 · cited 2×
“…pregnant women, and at-risk population groups [9,20–22]. global prevalence of HTLV-1 has been estimated to be anywhere between 3 and 30 million cases [18,19], with estimates based primarily on the serological screening of blood donors, pregnant women, and at-risk population groups [9,20–22].”
BackgroundNishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H. P., & Taguchi, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.05.026 · Cited by 58 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Immunogenetics of HTLV-I/II and Associated Diseases
Sonoda, S., Fujiyoshi, T., & Yashiki, S. (1996) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199600001-00020 · Cited by 58
Einsiedel, L., Pham, H., Wilson, K., Walley, R., Turpin, J., Bangham, C., Gessain, A., & Woodman, R. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006281 · Cited by 58 · cited 1×
“These studies demonstrated potent disruption of the HTLV-1 LTR promoter and subsequent proviral gene expression, anti-tumour effects in vivo, and, most importantly, apoptosis of HTLV-1-infected cells triggered by DSBs in the LTR.”
BackgroundHTLV-1 Yin and Yang: Rex and p30 master regulators of viral mRNA trafficking.
Baydoun, H. H., Bellon, M., & Nicot, C. (2008) · Aids Reviews · Cited by 56
Silic‐Benussi, M., Cannizzaro, E., Venerando, A., Cavallari, I., Petronilli, V., Rocca, N. L., Marin, O., Chieco‐Bianchi, L., Lisa, F. D., D’Agostino, D. M., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.02.001 · Cited by 56
Merezak, C., Pierreux, C. E., Adam, E., Lemaigre, F. P., Rousseau, G., Calomme, C., Lint, C. M. V., Christophe, D., Kerkhofs, P., Burny, A., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6977-6988.2001 · Cited by 56
Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent
Hirons, A., Khoury, G., & Purcell, D. F. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30328-5 · Cited by 56
Self-citationKannian, P., Yin, H., Doueiri, R., Lairmore, M. D., Fernandez, S., & Green, P. L. (2012) · Journal of Virology · doi:10.1128/jvi.06900-11 · Cited by 55 · cited 1×
“ART targets viral entry, life cycle, and replication but fail to eliminate HTLV-1 reservoirs due to overlooking their clonal expansion replication.”
BackgroundPLASMAPHERESIS IN TREATMENT OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I ASSOCIATED MYELOPATHY
Matsuo, H., Tsujihata, M., Satoh, A., Shirabe, S., Nakamura, T., Kinoshita, I., Tomita, I., Shibayama, K., & Nagataki, S. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90525-9 · Cited by 55 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundGlycogen-nucleic acid constructs for gene silencing in multicellular tumor spheroids
Wojnilowicz, M., Besford, Q. A., Wu, Y., Loh, X. J., Braunger, J. A., Glab, A., Cortez‐Jugo, C., Caruso, F., & Cavalieri, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.024 · Cited by 55
Haziot, M. E., Gascon, M. R., Assone, T., Fonseca, L. A. M., Luiz, O. D. C., Smid, J., Paiva, A. M., Marcusso, R. M. D. N., de Oliveira, A. C. P., & Casseb, J. (2019) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006967 · Cited by 55
Takahashi, M. M., Li, H., Zhou, J., Chomchan, P., Aishwarya, V., Damha, M. J., & Rossi, J. J. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.001 · Cited by 55 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundMiyazato, P., Yasunaga, J.-I., Taniguchi, Y., Koyanagi, Y., Mitsuya, H., & Matsuoka, M. (2006) · Journal of Virology · doi:10.1128/jvi.01009-06 · Cited by 54 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialIntegrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1
Seegulam, M. E., & Ratner, L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01413-10 · Cited by 54
Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/c-myc and Ig/tax genes.
Benvenisty, N., Ornitz, D. M., Bennett, G. L., Sahagan, B. G., Kuo, A. C., Cardiff, R. D., & Leder, P. (1992) · PubMed · Cited by 53
Living Invisible: HTLV-1-Infected Persons and the Lack of Care in Public Health
Zihlmann, K. F., de Alvarenga, A. T., & Casseb, J. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001705 · Cited by 52 · cited 1×
“HTLV-1 is a type of Deltaretrovirus, belonging to the Orthoretrovirinae subfamily, and causes life-long infection [5] in an estimated 10 million individuals worldwide across a vast geographical area, with endemic hotspots vastly limited to Indigenous populations [6–9].”
BackgroundSafety of long-term treatment of HAM/TSP patients with valproic acid
Olindo, S., Belrose, G., Gillet, N., Rodriguez, S., Boxus, M., Verlaeten, O., Asquith, B., Bangham, C., Signaté, A., Smadja, D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-349910 · Cited by 52 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundYi, G., Choi, J. G., Bharaj, P., Abraham, S., Dang, Y., Kafri, T., Alozie, O., Manjunath, M. N., & Shankar, P. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.52 · Cited by 52
Saito, M., Nakagawa, M., Kaseda, S., Matsuzaki, T., Jonosono, M., Eiraku, N., Kubota, R., Takenouchi, N., Nagai, M., Furukawa, Y., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380101 · Cited by 52
Sonoda, J., Koriyama, C., Yamamoto, S., Kozako, T., Li, H. C., Lema, C., Yashiki, S., Fujiyoshi, T., Yoshinaga, M., Nagata, Y., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02493.x · Cited by 51 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundGhorbel, S., Sinha-Datta, U., Dundr, M., Brown, M., Franchini, G., & Nicot, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603981200 · Cited by 51
Antoine Gessain, A., & Mahieux, R. (2000) · PubMed · Cited by 51
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific
Suzuki, K., Ishida, T., Yamagishi, M., Ahlenstiel, C., Swaminathan, S., Marks, K., Murray, D., McCartney, E. M., Beard, M. R., Alexander, M., et al. (2011) · RNA Biology · doi:10.4161/rna.8.6.16264 · Cited by 50 · cited 1×
“Both tax and hbz should be considered important gene targets, as they are increasingly implicated in persistence and disease induction.”
BackgroundSelf-citationChen, J., Zhang, M., Ju, W., & Waldmann, T. A. (2009) · Blood · doi:10.1182/blood-2008-04-149658 · Cited by 49 · cited 1×
“NHPs indeed recapitulate most aspects of viral infection, replication, and pathogenesis; however, the high cost of research and regulations underpin its scarce use in experimental research.”
BackgroundMacchi, B., Balestrieri, E., Ascolani, A., Hilburn, S., Martin, F., Mastino, A., & Taylor, G. P. (2011) · Viruses · doi:10.3390/v3050469 · Cited by 49 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundAntiviral effect of raltegravir on HTLV-1 carriers
Trevino, A., Parra, P., Bar-Magen, T., Garrido, C., de Mendoza, C., & Soriano, V. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr404 · Cited by 49 · cited 1×
“Given the absence of approved HTLV-1 antiviral therapeutics, the majority of readily available drugs only treat the symptoms of disease.”
BackgroundImmunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49
Antisense-Induced Guanine Quadruplexes Inhibit Reverse Transcription by HIV-1 Reverse Transcriptase
Hagihara, M., Yamauchi, L., Seo, A., Yoneda, K., Senda, M., & Nakatani, K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1032088 · Cited by 48 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundCoskun, A. K., & Sutton, R. E. (2005) · Journal of Virology · doi:10.1128/jvi.79.7.4150-4158.2005 · Cited by 48
Villamizar, O., Waters, S. A., Scott, T. A., Grepo, N., Jaffé, A., & Morris, K. V. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12053 · Cited by 48 · cited 1×
“Despite these challenges, the development of RNAi therapeutics has illuminated an exciting new modality of therapy and could have considerable implications for the future of treating HTLV-1.”
BackgroundSelf-citationTrentin, B., Rebeyrotte, N., & Mamoun, R. Z. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6504-6510.1998 · Cited by 47 · cited 9×
“…DNA provirus integration [30] Virion [33] here are also two regulatory proteins, Tax and Rex, which are trans-activators of transcription, the inhibition of which by the HTLV-1 p30II viral protein inhibits virus expression and suppresses Tax/HBZ-induced oxidative and metabolic toxicity [57,58].”
BackgroundInfluentialPotential immunogenicity of adult T cell leukemia cells in vivo
Kurihara, K., Harashima, N., Hanabuchi, S., Masuda, M., Utsunomiya, A., Tanosaki, R., Tomonaga, M., Ohashi, T., Hasegawa, A., Masuda, T., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20737 · Cited by 47 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
A novel therapeutic molecule against HTLV-1 infection targeting provirus
Tanaka, A., Takeda, S., Kariya, R., Matsuda, K., Urano, E., Okada, S., & Komano, J. (2013) · Leukemia · doi:10.1038/leu.2013.46 · Cited by 46 · cited 1×
“Argonaute 1 (Ago1) protein ushers the promoter–complementary siRNA to enter the nucleus and forms the RNA-induced transcriptional silencing (RITS) complex, which induces heritable, epigenetic modifications that repress transcription, thereby silencing gene expression [303] (Figure 5).”
BackgroundMolecular Mechanism of Tumorigenesis in Mice Transgenic for the Human T Cell Leukemia VirusTaxGene
Coscoy, L., Gonzalez‐Dunia, D., Tangy, F., Syan, S., Brahic, M., & Ozden, S. (1998) · Virology · doi:10.1006/viro.1998.9298 · Cited by 46
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2
Scott, T. A., Supramaniam, A., Idris, A., Cardoso, A. A., Shrivastava, S., Kelly, G., Grepo, N., Soemardy, C., Ray, R. M., McMillan, N. A. J., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.015 · Cited by 44 · cited 1×
“Despite these challenges, the development of RNAi therapeutics has illuminated an exciting new modality of therapy and could have considerable implications for the future of treating HTLV-1.”
BackgroundSelf-citationEinsiedel, L., Chiong, F., Jersmann, H., & Taylor, G. P. (2021) · Retrovirology · doi:10.1186/s12977-020-00543-z · Cited by 43 · cited 2×
“Cont.”
BackgroundNakamura, H., Tanaka, Y., Komuro, A., Ishikawa, K.-I., Takadaya, K., Tozawa, H., Tsujimoto, H., Honjo, S., & Hayami, M. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380614 · Cited by 42 · cited 1×
“This section discusses current interventions, with a focus on the limitations of ART in the treatment of HTLV-1 and its associated diseases.”
BackgroundMerimi, M., Klener, P., Szynal, M., Cleuter, Y., Bagnis, C., Kerkhofs, P., Burny, A., Martiat, P., & den Broeke, A. V. (2007) · Retrovirology · doi:10.1186/1742-4690-4-51 · Cited by 42
Animal models on HTLV-1 and related viruses: what did we learn?
Hajj, H. E., Nasr, R., Kfoury, Y., Dassouki, Z., Nasser, R., Kchour, G., Hermine, O., Thé, H. D., & Bazarbachi, A. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00333 · Cited by 42
Baratella, M., Forlani, G., Raval, G. U., Tedeschi, A., Gout, O., Gessain, A., Tosi, G., & Accolla, R. S. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005285 · Cited by 42 · cited 1×
“…patient populations in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will benefit from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmitted…”
BackgroundDegeneration of oxidative muscle fibers in HTLV-1 tax transgenic mice.
Nerenberg, M. I., & Wiley, C. A. (1989) · PubMed · Cited by 41
Characterization of MT-2 cells as a human regulatory T cell-like cell line
Hamano, R., Wu, X., Wang, Y., Oppenheim, J. J., & Chen, X. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.123 · Cited by 41 · cited 1×
“Other deltaretroviridae include the simian T-lymphotropic virus (STLV-1) and bovine leukaemia virus (BLV), both with large bodies of work useful for modelling HTLV-1 infection.”
BackgroundProapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-κB pathway
Kfoury, Y., Nasr, R., Hermine, O., de Thé, H., & Bazarbachi, A. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401624 · Cited by 40 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma
El Hajj, H., Khalil, B., Ghandour, B., Nasr, R., Shahine, S., Ghantous, A., Abdel-Samad, R., Sinjab, A., Hasegawa, H., Jabbour, M., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560060 · Cited by 40 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
(2015) · Journal of Cancer Sciences · doi:10.13188/2377-9292.1000009 · Cited by 40 · cited 1×
“The New Zealand White rabbit model was used to determine the transformation timepoint of HTLV-1 tropism [155].”
MethodIntermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
Kataoka, A., Imai, H., Inayoshi, S., & Tsuda, T. (1993) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.11.1213 · Cited by 39 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundPanfil, A. R., Dissinger, N. J., Howard, C. M., Murphy, B. M., Landes, K., Fernandez, S. A., & Green, P. L. (2016) · Journal of Virology · doi:10.1128/jvi.03113-15 · Cited by 39
Coler-Reilly, A. L. G., Sato, T., Matsuzaki, T., Nakagawa, M., Niino, M., Nagai, M., Nakamura, T., Takenouchi, N., Araya, N., Yagishita, N., et al. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0533-z · Cited by 39 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundMartin, F., Castro, H., Gabriel, C., Adonis, A., Fedina, A., Harrison, L., Brodnicki, L., Demontis, M. A., Babiker, A. G., Weber, J. N., et al. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001675 · Cited by 38 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundRegulation of Expression and Latency in BLV and HTLV
Pluta, A., Jaworski, J. P., & Douville, R. N. (2020) · Viruses · doi:10.3390/v12101079 · Cited by 38
Barski, M. S., Minnell, J. J., & Maertens, G. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01877 · Cited by 37 · cited 1×
“Given the absence of approved HTLV-1 antiviral therapeutics, the majority of readily available drugs only treat the symptoms of disease.”
BackgroundZimmerman, B., Sargeant, A., Landes, K., Fernandez, S. A., Chen, C.-S., & Lairmore, M. D. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.07.015 · Cited by 36 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Pise-Masison, C. A., Dittmer, J., Clemens, K. E., & Brady, J. N. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1236 · Cited by 36
Ye, L., Taylor, G. P., & Rosadas, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832430 · Cited by 36
Transmission of Human T-Cell Leukemia Virus Type 1 to Mice
Fang, J., Kushida, S., Feng, R., Tanaka, M., Kawamura, T., Abe, H., Maeda, N., Onobori, M., Hori, M., Uchida, K., et al. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.3952-3957.1998 · Cited by 35 · cited 1×
“The first HTLV-1 Tax transgenic mice were developed in 1987, originally called HTLV-1 Tat, controlled by the LTR promoter [138].”
MethodA safe and effective vaccine against bovine leukemia virus
Suárez Archilla, G., Gutiérrez, G., Camussone, C., Calvinho, L., Abdala, A., Alvarez, I., Petersen, M., Franco, L., Destefano, G., Monti, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980514 · Cited by 34
Balestrieri, E., Forte, G., Matteucci, C., Mastino, A., & Macchi, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3080-3083.2002 · Cited by 33 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialTsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1212-4 · Cited by 33 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundIda, H., Kurata, A., Eguchi, K., Yamashita, I., Nakashima, M., Sakai, M., Kawabe, Y., Nakamura, T., & Nagataki, S. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90041-8 · Cited by 32
Trends in HTLV‐1 prevalence and incidence of adult T‐cell leukemia/lymphoma in Nagasaki, Japan
Koga, Y., Iwanaga, M., Soda, M., Inokuchi, N., Sasaki, D., Hasegawa, H., Yanagihara, K., Yamaguchi, K., Kamihira, S., & Yamada, Y. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21738 · Cited by 32
ISG15 deficiency restricts HIV-1 infection
Jurczyszak, D., Manganaro, L., Buta, S., Gruber, C., Martin-Fernandez, M., Taft, J., Patel, R. S., Cipolla, M., Alshammary, H., Mulder, L. C. F., et al. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010405 · Cited by 32 · cited 1×
“As has an exceptionally conserved genome, it is a HTLV-1 has an exceptionally conserved genome, it is a promising candidate for the sequence-specific and highly potent RNAi. promising candidate for the sequence-spe-ci fi c and highly potent RNAi.”
BackgroundQ-C Araújo, A., Afonso, C. R., Leite, A. C. B., & Dultra, S. V. (1993) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1993000300005 · Cited by 31
Moens, B., Decanine, D., Menezes, S. M., Khouri, R., Silva-Santos, G., López, G., Álvarez, C., Talledo, M., Gotuzzo, E., Kruschewsky, R. D. A., et al. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001729 · Cited by 31 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundCOHORT EFFECT ON HTLV-I SEROPREVALENCE IN SOUTHERN JAPAN
UEDA, K. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90986-0 · Cited by 31
Arimura, K., Nakagawa, M., Izumo, S., Usuku, K., Itoyama, Y., Kira, J.-I., & Osame, M. (2007) · Journal of Neurovirology · doi:10.1080/13550280701397627 · Cited by 31
Molecular targeting for treatment of human T-lymphotropic virus type 1 infection
Soltani, A., Hashemy, S. I., Zahedi Avval, F., Soleimani, A., Rafatpanah, H., Rezaee, S. A., Griffith, R., & Mashkani, B. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.139 · Cited by 31 · cited 2×
“Aggressive forms of ATL are treated with intensive chemotherapy, coupled with concurrent or low-dose azidothymidine, an NRTI developed for HIV-AIDS, and interferon-alpha (AZT/IFN-α ) for maintenance [194].”
BackgroundInfluentialYamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses · doi:10.3390/v14010136 · Cited by 31 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundHleihel, R., Skayneh, H., de Thé, H., Hermine, O., & Bazarbachi, A. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00841-7 · Cited by 31 · cited 1×
“The New Zealand White rabbit model was used to determine the transformation timepoint of HTLV-1 tropism [155].”
MethodIshihara, S., TACHIBANA, N., Okayama, A., Murai, K., Tsuda, K., & Mueller, N. L. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00108.x · Cited by 29 · cited 1×
“In squirrel monkeys and cynomolgus monkeys, inoculation with MT-2 cells showed spontaneous expression of IL2 and HTLV-1 proteins in PBMCs [151].”
BackgroundAndrade, R. G., Gonçalves, P. D. C., Ribeiro, M. A., Romanelli, L. C. F., Ribas, J. G., Torres, E. B., Carneiro-Proietti, A. B. D. F., Barbosa-Stancioli, E. F., & Martins, M. L. (2013) · Journal of Clinical Virology · doi:10.1016/j.jcv.2012.10.003 · Cited by 29 · cited 1×
“…patient populations in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will benefit from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmitted infections.”
BackgroundShirinian, M., Kambris, Z., Hamadeh, L., Grabbe, C., Journo, C., Mahieux, R., & Bazarbachi, A. (2015) · Journal of Virology · doi:10.1128/jvi.00918-15 · Cited by 29 · cited 1×
“The cessation of therapy in HIV is associated with a strong viral rebound to pre-therapeutic plasma viral loads [164–166] and may be similarly mimicked in the incidence of successful treatment of HTLV-1 with ART.”
BackgroundTamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02110 · Cited by 29 · cited 2×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundLai, M., Maori, E., Quaranta, P., Matteoli, G., Maggi, F., Sgarbanti, M., Crucitta, S., Pacini, S., Turriziani, O., Antonelli, G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01358-21 · Cited by 28 · cited 1×
“As has an exceptionally conserved genome, it is a HTLV-1 has an exceptionally conserved genome, it is a promising candidate for the sequence-specific and highly potent RNAi. promising candidate for the sequence-spe-ci fi c and highly potent RNAi.”
BackgroundStructural Basis for HTLV-1 Protease Inhibition by the HIV-1 Protease Inhibitor Indinavir
Kuhnert, M., Steuber, H., & Diederich, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500402c · Cited by 27 · cited 1×
“ATL therapeutic strategies for patients are determined largely by clinical subtype (acute, lymphoma, chronic, and smouldering) [12,193].”
BackgroundKatoh, T., Harada, T., Morkawa, S., & Wakutani, T. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380218 · Cited by 27 · cited 1×
“Three months post infection, HTLV-1 provirus was detected in PBMCs and lymphoid organs.”
BackgroundPromoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription
Suzuki, K., Ahlenstiel, C., Marks, K., & Kelleher, A. D. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.67 · Cited by 26
Self-citationBeilke, M. A., Traina‐Dorge, V., England, J. D., & Blanchard, J. L. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390410 · Cited by 26 · cited 1×
“This section discusses current interventions, with a focus on the limitations of ART in the treatment of HTLV-1 and its associated diseases.”
BackgroundTarasevich, A., Filatov, A., Pichugin, A., & Mazurov, D. (2015) · Acta virologica · doi:10.4149/av_2015_03_247 · Cited by 26
Mozhgani, S., Jahantigh, H. R., Rafatpanah, H., et al. (2018) · Neurodegenerative Diseases · doi:10.1159/000490058 · Cited by 26
RNAi therapeutics: an antiviral strategy for human infections
Kelleher, A. D., Cortez‐Jugo, C., Cavalieri, F., Qu, Y., Glanville, A. R., Caruso, F., Symonds, G. P., & Ahlenstiel, C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.09.011 · Cited by 26 · cited 1×
“An eradication approach in the treatment of latently infected HIV-1 cells is known as the “shock and kill” technique, which aims to re-activate infected cells by “shocking” them using latency-reversing agents (LRAs), TGS is localised to the nucleus and is ) RNA-binding protein; TNRC6, trinucleotide…”
BackgroundSelf-citationNovel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Bowden-Reid, E., Ledger, S., Zhang, Y., Giallonardo, F. D., Aggarwal, A., Stella, A. O., Akerman, A., Milogiannakis, V., Walker, G. J., Rawlinson, W. D., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105677 · Cited by 26 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundSelf-citationZhang, J., Balestrieri, E., Grelli, S., Matteucci, C., Pagnini, V., D'Agostini, C., Mastino, A., & Macchi, B. (2001) · Virus Research · doi:10.1016/s0168-1702(01)00285-4 · Cited by 25 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialSix Colombian Patients with Adult T–Cell Leukemia/Lymphoma
Blank, A., Yamaguchi, K., Blank, M., Zaninovic, V., Sonoda, S., & Takatsuki, K. (1993) · Leukemia & Lymphoma · doi:10.3109/10428199309148542 · Cited by 25
Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure
Littleton, E. T. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.5.650 · Cited by 24 · cited 1×
“Establishing clinically useful biomarkers will prove instrumental in revolutionising patient care and clinical research.”
BackgroundUnderstanding the immunopathogenesis of inclusion-body myositis: present and future prospects.
Mc, D. (2002) · PubMed · Cited by 24
Hutchison, T., Malu, A., Yapindi, L., Bergeson, R., Peck, K., Romeo, M., Harrod, C. K., Pope, J., Smitherman, L., Gwinn, W., et al. (2018) · Virology · doi:10.1016/j.virol.2018.05.007 · Cited by 24 · cited 1×
“NHPs indeed recapitulate most aspects of viral infection, replication, and pathogenesis; however, the high cost of research and regulations underpin its scarce use in experimental research.”
BackgroundWhat we are learning on HTLV-1 pathogenesis from animal models
Dodon, M. D., Villaudy, J., Gazzolo, L., Haines, R., & Lairmore, M. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00320 · Cited by 23 · cited 1×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundRabaaoui, S., Zouhiri, F., Lançon, A., Leh, H., d'Angelo, J., & Wattel, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-07 · Cited by 23 · cited 1×
“Given the absence of approved HTLV-1 antiviral therapeutics, the majority of readily available drugs only treat the symptoms of disease.”
BackgroundYurick, D., Khoury, G., Clemens, B., Loh, L., Pham, H., Kedzierska, K., Einsiedel, L., & Purcell, D. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01063-18 · Cited by 23
Self-citationRisk of human T‐lymphotropic virus type I‐associated diseases in Jamaica with common HLA types
Goedert, J. J., Li, H., Gao, X., Chatterjee, N., Sonoda, S., Biggar, R. J., Cranston, B., Kim, N., Carrington, M. N., Morgan, O., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22767 · Cited by 22
Maeda, M., Tanabe-Shibuya, J., Miyazato, P., Masutani, H., Yasunaga, J.-I., Usami, K., Shimizu, A., & Matsuoka, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00356 · Cited by 22
Jinno-Oue, A., Tanaka, A., Shimizu, N., Mori, T., Sugiura, N., Kimata, K., Isomura, H., & Hoshino, H. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0156 · Cited by 21 · cited 1×
“Despite the prospect of IN inhibitors as an anti-HTLV-1 treatment option, it may prove futile when addressing the oversaturated population of people chronically infected with HTLV-1.”
BackgroundEinsiedel, L. J., Chiong, F. J. K., Jersmann, H. P. A., & Taylor, G. P. (2021) · Retrovirology · doi:10.1186/s12977-021-00549-1 · Cited by 21
Sato, T., Nagai, M., Watanabe, O., Misu, T., Takenouchi, N., Ohkubo, R., Ishihara, S., Tsuboi, Y., Katsuno, M., Nakagawa, M., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12239-x · Cited by 21 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundXiang, D., Yuan, Y., Chen, L., Liu, X., Belani, C., & Cheng, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.120 · Cited by 20 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ
Akkouche, A., Moodad, S., Hleihel, R., Skayneh, H., Chambeyron, S., El Hajj, H., & Bazarbachi, A. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009219 · Cited by 20 · cited 1×
“The cessation of therapy in HIV is associated with a strong viral rebound to pre-therapeutic plasma viral loads [164–166] and may be similarly mimicked in the incidence of successful treatment of HTLV-1 with ART.”
BackgroundRocha–Junior, M. C., Haddad, R., Alves, D. C. C., Wagatsuma, V. M. D. D., Mendes‐Junior, C. T., Deghaide, N. H. S., Takayanagui, O. M., Covas, D. T., Donadi, E. A., & Kashima, S. H. (2012) · Tissue Antigens · doi:10.1111/j.1399-0039.2012.01887.x · Cited by 19
Balestrieri, E., Sciortino, M. T., Mastino, A., & Macchi, B. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.09.001 · Cited by 19 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialTalukder, M. R., Woodman, R., Pham, H., Wilson, K., Gessain, A., Kaldor, J., & Einsiedel, L. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac614 · Cited by 19 · cited 2×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundKikuchi, T., Saijo, Y., Sakai, T., et al. (1996) · Internal Medicine · doi:10.2169/internalmedicine.35.305 · Cited by 18 · cited 1×
“As detailed in previous sections, the absence of predictors for disease progression in HTLV-1 infection is an unaddressed gap in the current literature.”
BackgroundLivengood, J. A., & Nyborg, J. K. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh590 · Cited by 18
Queiroz, M. A. F., Azevedo, V. N., Amoras, E. D. S. G., Moura, T. C. F., Ishak, M. D. O. G., Ishak, R., Vallinoto, A. C. R., & Feitosa, R. N. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00795 · Cited by 18
Shioda, S., Kasai, F., Watanabe, K., Kawakami, K., Ohtani, A., Iemura, M., Ozawa, M., Arakawa, A., Hirayama, N., Kawaguchi, E., et al. (2018) · Royal Society Open Science · doi:10.1098/rsos.172472 · Cited by 18 · cited 1×
“HTLV-1 does not productively infect murine cells and must be first inoculated to establish persistent infection.”
BackgroundTsukamoto, T. (2018) · AIDS · doi:10.1097/qad.0000000000001882 · Cited by 18 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundHTLV-1-associated arthropathy treated with anti-TNF-alpha agent
Frenzel, L., Moura, B., Marçais, A., et al. (2013) · Joint Bone Spine · doi:10.1016/j.jbspin.2013.10.006 · Cited by 17 · cited 1×
“Many treatments thus far for HTLV-1 have been repurposed from other diseases, so the current state of therapeutics will benefit from novel approaches.”
BackgroundHTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice
Ginwala, R., Caruso, B., Khan, Z. K., Pattekar, A., Chew, G. M., Corley, M. J., Loonawat, R., Jacobson, S., Sreedhar, S., Ndhlovu, L. C., et al. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9740-y · Cited by 17
CRISPR Genome Editing Applied to the Pathogenic Retrovirus HTLV-1
Panfil, A. R., Green, P. L., & Yoder, K. E. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.580371 · Cited by 17 · cited 1×
“…This was addressed using viral delivery methods to provide long-term siRNA expression, but this solution does not come without its caveats, as the over-saturation of cellular machinery may pose risks of toxicity and o ff -target e ff ects [304–306]. thereby silencing gene expression [303] (Figure 5).”
BackgroundYao, J., Grant, C. W., Harhaj, E. W., Nonnemacher, M. R., Alefantis, T. G., Martin, J., Jain, P., & Wigdahl, B. L. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.262 · Cited by 16
Oka, S., Ōno, K., & Nohgawa, M. (2019) · Leukemia Research Reports · doi:10.1016/j.lrr.2019.04.001 · Cited by 16 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Fazio, A. L., Kendle, W., Hoang, K., Korleski, E., Lemasson, I., & Polakowski, N. J. (2019) · Journal of Virology · doi:10.1128/jvi.00608-19 · Cited by 16
Early-Onset HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
Schwalb, A., Pérez-Muto, V., Cachay, R., Tipismana, M., Álvarez, C., Mejía, F., González-Lagos, E., & Gotuzzo, E. (2020) · Pathogens · doi:10.3390/pathogens9060450 · Cited by 16 · cited 1×
“HTLV-1-associated uveitis Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s…”
BackgroundKoseki, A., Araya, N., Yamagishi, M., Yamauchi, J., Yagishita, N., Takao, N., Takahashi, K., Kunitomo, Y., Honma, D., Araki, K., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1175762 · Cited by 16 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Balestrieri, E., Ascolani, A., Igarashi, Y., OKI, T., Mastino, A., Balzarini, J. M., & Macchi, B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01671-07 · Cited by 15 · cited 1×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundLee, Q., Mocarski, M., & Sun, S. X. (2016) · PubMed Central · Cited by 14
Morris, K. V., & Witwer, K. W. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.015 · Cited by 14 · cited 1×
“Along with the novelty of siRNA therapeutics, there are still many challenges posed for the literature to address, including efficient and targeted delivery and clinical translation.”
BackgroundSelf-citationMatsuura, E., Yoshimura, A., Nozuma, S., Higuchi, I., Kubota, R., & Takashima, H. (2015) · BMC Neurology · doi:10.1186/s12883-015-0275-7 · Cited by 13 · cited 1×
“Cont.”
High level of genomic divergence in orf-I p12 and hbz genes of HTLV-1 subtype-C in Central Australia
Hirons, A., Yurick, D., Jansz, N., Ellenberg, P., Franchini, G., Einsiedel, L., Khoury, G., & Purcell, D. F. J. (2024) · Retrovirology · doi:10.1186/s12977-024-00647-w · Cited by 13 · cited 1×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundSelf-citationEnose-Akahata, Y., Ngouth, N., Ohayon, J., Mandel, M., Chavin, J., Turner, T. J., & Jacobson, S. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000986 · Cited by 13 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundHuman T lymphotropic virus I infection deregulates surface expression of the transferrin receptor.
Vidal, C., Matsushita, S., Colamonici, O. R., Trepel, J. B., Mitsuya, H., & Neckers, L. M. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.3.984 · Cited by 12 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Danazol a new perspective in the treatment of htlv-l associated myelopathy (preliminary report)
Melo, A., Moura, L., Meireles, A., & Costa, G. (1992) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1992000300025 · Cited by 12
(1997) · PubMed · Cited by 12
Fernandez, M. V., Delviks‐Frankenberry, K. A., Scheiblin, D. A., Happel, C., Pathak, V. K., & Freed, E. O. (2019) · Journal of Virology · doi:10.1128/jvi.01390-19 · Cited by 12 · cited 1×
“Over the past three decades, a variety of animal models have been developed to help elucidate the events of HTLV-1 pathogenesis and evaluate novel therapeutics.”
BackgroundMartella, C., Tollenaere, A. I., Waast, L., Lacombe, B., Groussaud, D., Margottin-Goguet, F., Ramirez, B. C., & Pique, C. (2020) · Journal of Virology · doi:10.1128/jvi.02171-19 · Cited by 12 · cited 1×
“Rabbits inoculated with HTLV-1 do not develop HTLV-1-associated diseases; however, they present with persistent HTLV-1 infection.”
BackgroundHTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review
Bradshaw, D., & Taylor, G. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.881547 · Cited by 12 · cited 1×
“This follows precedent set by the success of the mRNA COVID-19 vaccines and the five FDA-approved siRNA therapeutics and further highlights the potential for antiviral RNA-based therapeutics.”
BackgroundMirsaliotis, A., Lamb, D., & Brighty, D. W. (2008) · Journal of Virology · doi:10.1128/jvi.02458-07 · Cited by 11 · cited 1×
“A study in 2008 examined the effects of SQLs and pre-established HIV-1 IN-targeted DKAs in an in vitro strand-transfer assay and ex vivo infection of PBMCs with lethally irradiated HTLV-1-positive MT2 cells [187].”
BackgroundHuman T-cell leukemia virus type 1 can infect a wide variety of cells in mice
Feng, R., Tanaka, M., Abe, H., Arashi, N., Sun, B., Uchida, K., & Miwa, M. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00664.x · Cited by 11 · cited 1×
“…mice leads to oncogenesis and other less typical manifestations of HTLV-1 infection; however, leukaemia/lymphoma induction is rare and does not fully capture the disease environment, but it has been useful to elucidate the role that tax plays in the disruption of T cell function and establish…”
BackgroundPolyarthritis in HTLV-1-infected patients. A review of 17 cases.
Guérin, B., Arfi, S., Numéric, P., et al. (1995) · PubMed · Cited by 11
Bellon, M., & Nicot, C. (2022) · Journal of Virology · doi:10.1128/jvi.01960-21 · Cited by 11 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Talukder, M. R., Pham, H., Woodman, R., Wilson, K., Taylor, K., Kaldor, J., & Einsiedel, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042084 · Cited by 11 · cited 1×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundRevlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Raedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 11
Shirdel, A., Azarpazhooh, M. R., Sahebari, M., Ghanbari, M., Mirfeizi, S. Z., Hutchinson, I. V., Ziaee, A., & Rafatpanah, H. (2013) · PubMed Central · Cited by 10
Nagai, M., Tsujii, T., Iwaki, H., Nishikawa, N., & Nomoto, M. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0869 · Cited by 10 · cited 2×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundTalukder, M. R., Clauss, C. S., Cherian, S., Woodman, R., & Einsiedel, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27163 · Cited by 10
PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
Gao, L., Yang, J., Feng, J.-T., Liu, Z., Dong, Y., Luo, J., Yu, L., Wang, J., Fan, H., Ma, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856463 · Cited by 10
(1984) · PubMed · Cited by 9
Fowler, F., & Einsiedel, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.845594 · Cited by 9
Cyclosporin a inhibits HTLV‐I tax expression and shows anti‐tumor effects in combination with VP‐16
Ozaki, A., Arima, N., Matsushita, K., Uozumi, K., Akimoto, M., Hamada, H., Kawada, H., Horai, S., Tanaka, Y., & Tei, C. (2007) · Journal of Medical Virology · doi:10.1002/jmv.21028 · Cited by 8 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Winter, H. Y., Dayaram, T., & Marriott, S. J. (2007) · Journal of Virology · doi:10.1128/jvi.00968-07 · Cited by 8
Miwa (2009) · International Journal of Oncology · doi:10.3892/ijo_00000382 · Cited by 8 · cited 1×
“…mice leads to oncogenesis and other less typical manifestations of HTLV-1 infection; however, leukaemia/lymphoma induction is rare and does not fully capture the disease environment, but it has been useful to elucidate the role that tax plays in the disruption of T cell function and establish its…”
BackgroundMirsaliotis, A., Nurkiyanova, K., Lamb, D., Kuo, C.-W. S., & Brighty, D. W. (2007) · Journal of General Virology · doi:10.1099/vir.0.82390-0 · Cited by 8 · cited 1×
“A study in 2008 examined the effects of SQLs and pre-established HIV-1 IN-targeted DKAs in an in vitro strand-transfer assay and ex vivo infection of PBMCs with lethally irradiated HTLV-1-positive MT2 cells [187].”
BackgroundSalvador (2015) · doi:10.1097/md.0000000000000382 · Cited by 7 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
Background150 Practice ECGs: Interpretation and Review
Taylor, G. J. (2006) · doi:10.1002/9780470693964 · Cited by 7
Global HTLV-1/2 Burden and Associated Diseases
Williams, C. K. O. (2019) · Cancer and AIDS · doi:10.1007/978-3-319-99235-8_2 · Cited by 6 · cited 1×
“HTLV-1 was first identified as the aetiologic agent of adult T cell lymphoma/leukaemia (ATL) [10], with the prevalence of 5% amongst carriers [11,12].”
BackgroundScott, T. A., Soemardy, C., Ray, R. M., & Morris, K. V. (2023) · NAR Cancer · doi:10.1093/narcan/zcac046 · Cited by 6 · cited 1×
“Despite these challenges, the development of RNAi therapeutics has illuminated an exciting new modality of therapy and could have considerable implications for the future of treating HTLV-1.”
BackgroundSelf-citationHTLV-I and –II seroprevalence among United States blood donors, 2000-2009
Kaidarova, Z., & Murphy, E. L. (2011) · Retrovirology · doi:10.1186/1742-4690-8-s1-a74 · Cited by 5 · cited 2×
“…million cases [18,19], with estimates based primarily on the serological screening of blood donors, pregnant women, and at-risk population groups [9,20–22]. global prevalence of HTLV-1 has been estimated to be anywhere between 3 and 30 million cases [18,19], with estimates based primarily on the…”
BackgroundCentral Africa: cradle of divergent PTLV types
Dooren, S. V. (2005) · Lirias · Cited by 5
Bastos Ferreira, A. P., do Nascimento, A. D. F. S., & Sampaio Rocha-Filho, P. A. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-021-01043-2 · Cited by 5
(1991) · PubMed · Cited by 4
Kayikcioglu, O. R., Cheng, L., Kozak, I., Bergeron-Lynn, G., Schulteis, C. T., Rhoades, K. L., & Freeman, W. R. (2006) · Current Eye Research · doi:10.1080/02713680600672177 · Cited by 3
Rinite crônica em portadores do HTLV-1: estudo histopatológico
Gaspar-Sobrinho, F. P., Souza‐Machado, A., Cruz, Á. A., et al. (2012) · Brazilian Journal of Otorhinolaryngology · doi:10.1590/s1808-86942012000200007 · Cited by 1 · cited 1×
“Cont.”
Research works printed but not linked: 2
- Ribas, 2002, Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil, Rev. Soc. Bras. Med. Trop., 35, 499
- Cruz, 2012, Chronic rhinitis in HTLV-1 carriers: A histopathologic study, Braz. J. Otorhinolaryngol., 78, 35
Cited by
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Branda, F., Romano, C., Pavia, G., Bilotta, V., Locci, C., Azzena, I., Deplano, I., Pascale, N., Perra, M. T., Giovanetti, M., et al. (2025) · Viruses · doi:10.3390/v17050664 · Cited by 47
“Currently, treatment options for HTLV-1 are limited and focus primarily on symptom management, with few curative interventions available [171].”
Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo
Cooney, J. P., Hirons, A., Jansz, N., Allison, C. C., Hickey, P. F., Teh, C. E., Tan, T., Dagley, L. F., Yousef, J. M., Yurick, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.023 · Cited by 18
Self-citationOncoviruses in the Oral Cavity: Recent Advances in Understanding Viral Infections and Tumorigenesis
Campos, L., Guimarães, A. C. S., Pereira, J. G., da Silva, C. S., de Almeida, N. A. A., Marinho, P. D. N., de Sousa, R. M. P., Duś‐Ilnicka, I., & de Paula, V. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146721 · Cited by 10
“Therefore, this vaccine may provide a model against HTLV-1 that requires the stimulation of humoral and cytotoxic immune responses [274,278].”
Mikame, Y., Toyama, H., Dohno, C., Wada, T., & Yamayoshi, A. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01416-2 · Cited by 5
Metadata
- Authors
- Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L.
- Affiliations
- UNSW Sydney (AU)
- The University of Melbourne (AU)
- Queensland University of Technology (AU)
- Corresponding author
- Ahlenstiel, Chantelle L.
- ORCID
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2024-10-15
- Volume
- 16
- Issue
- 10
- Pages
- 1616
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC11512412
- OpenAlex
- W4403429851
- Cited by
- 22
- References
- 372
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- an Australian Government Research Training Program Scholarship (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- an NHMRC programme grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a UNSW Rapid Response Research grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the NSW RNA Production Research Network (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a philanthropic grant to the Immunotherapy Research Fund at the Kirby Institute (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the Australian NHMRC Ideas grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the ACH4 and the Phyllis Connor Memorial Trust (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- NIH (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HTLV-1, antiviral agents, gene therapy, adult T-cell leukemia/lymphoma, tropical spastic paraparesis, retroviral infection, CD4+ T cells, HIV-1, vaccine development, animal models, oncogenic retroviruses
- MeSH terms
- Animals, Antiviral Agents, Humans, Viral Vaccines, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.